

Broker Briefing



Innate Immuno**therapeutics**

Simon Wilkinson
Chief Executive Officer

Innate Immunotherapeutics (ASX:IIL) is an Australian biotechnology company which is currently conducting a Phase 2B efficacy trial of a drug candidate, MIS416, to treat secondary progressive multiple sclerosis (SPMS). There are currently no safe and effective ongoing treatments for this progressive and highly disabling form of multiple sclerosis. Innate has completed successful Phase 1B/2A trials which have demonstrated an acceptable safety and tolerability profile.



ANALYTICA

Geoff Daly
Chief Executive Officer

Analytica is a Brisbane-based life sciences company. Its lead product is the PeriCoach™ system - an e-health treatment system for women who suffer Stress Urinary Incontinence. PeriCoach™ comprises a device, web portal and smartphone app. The device evaluates activity in pelvic floor muscles. This information is transmitted to a smartphone app and can be loaded to PeriCloud where physicians can monitor patient progress via web portal. This novel system enables physicians to remotely determine if a woman is performing her pelvic floor exercises and if these are improving her condition.



ortho·cell

Alex McHenry
Chief Operating Officer

Orthocell is an Australian regenerative medicine company dedicated to the improvement of the lives of people suffering from soft tissue injuries and subsequent chronic musculoskeletal disorders. To date the Company has successfully developed and commenced commercialisation of two autologous cell therapies. Orthocell has also developed and is readying for registration, a collagen scaffold product for the repair and reconstruction of soft tissue injuries such as tendon tears, hernias and tympanic membrane reconstructions.



opal Biosciences

Julie Phillips
Chief Executive Officer /
Managing Director

With the rise in antibiotic resistance and few new ones in development, novel effective treatment for infections have the potential to be life-saving. Opal Biosciences Limited is an innovative player in infectious disease treatment, committed to tackling this serious global health threat. With programs running in the USA already, Opal is well positioned strategically and has the potential to provide investors with substantial returns.



The afternoon will be chaired by Ben Walsh, Senior Account Manager - Investor Communication, Buchan

This Broker Briefing event is hosted by
Vertical Events & Buchan

Buchan

A WAGGENER EDSTROM PARTNER

events

Resource Conference Specialists